Tasly Pharmaceutical Signs Cooperation Deal for CAR-T Drug

MT Newswires Live03-20 10:57

Tasly Pharmaceutical (SHA:600535) signed a cooperation agreement for the research and development and marketing of a dual-target CAR-T, according to a Shanghai bourse filing on Friday.

The contract was signed with Beijing Neurosurgical Institute and Beijing Renceng Neuro-Oncology Biotechnology Engineering Research Center.

All parties will develop the drug, sharing research and development costs of up to 240 million yuan. Tasly exclusively owns the manufacturing and commercialization of the drugs.

The drug, which is undergoing phase I clinical trials, was developed for the treatment of recurrent glioblastoma. It is targeting CD44 and/or CD133.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620004206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 10:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620004206","market":"sg","top_or_hot":-1,"title":"Tasly Pharmaceutical Signs Cooperation Deal for CAR-T Drug","media":"MT Newswires Live","content":"<html><body><p> Tasly Pharmaceutical (SHA:600535) signed a cooperation agreement for the research and development and marketing of a dual-target CAR-T, according to a Shanghai bourse filing on Friday.</p><p>The contract was signed with Beijing Neurosurgical Institute and Beijing Renceng Neuro-Oncology Biotechnology Engineering Research Center.</p><p>All parties will develop the drug, sharing research and development costs of up to 240 million yuan. Tasly exclusively owns the manufacturing and commercialization of the drugs.</p><p>The drug, which is undergoing phase I clinical trials, was developed for the treatment of recurrent glioblastoma. It is targeting CD44 and/or CD133.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tasly Pharmaceutical Signs Cooperation Deal for CAR-T Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTasly Pharmaceutical Signs Cooperation Deal for CAR-T Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-20 10:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tasly Pharmaceutical (SHA:600535) signed a cooperation agreement for the research and development and marketing of a dual-target CAR-T, according to a Shanghai bourse filing on Friday.</p><p>The contract was signed with Beijing Neurosurgical Institute and Beijing Renceng Neuro-Oncology Biotechnology Engineering Research Center.</p><p>All parties will develop the drug, sharing research and development costs of up to 240 million yuan. Tasly exclusively owns the manufacturing and commercialization of the drugs.</p><p>The drug, which is undergoing phase I clinical trials, was developed for the treatment of recurrent glioblastoma. It is targeting CD44 and/or CD133.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4230","symbol_name":"旅客陆运","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2620004206","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620004206","pubTimestamp":1773975431,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tasly Pharmaceutical  signed a cooperation agreement for the research and development and marketing of a dual-target CAR-T, according to a Shanghai bourse filing on Friday.The contract was signed with Beijing Neurosurgical Institute and Beijing Renceng Neuro-Oncology Biotechnology Engineering Research Center.All parties will develop the drug, sharing research and development costs of up to 240 million yuan. Tasly exclusively owns the manufacturing and commercialization of the drugs.The drug, which is undergoing phase I clinical trials, was developed for the treatment of recurrent glioblastoma. It is targeting CD44 and/or CD133.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600535":"天士力","BK4230":"旅客陆运","BK0012":"证金概念","BK0196":"行业龙头","CAR":"安飞士","BK0028":"国家队","BK0239":"医药制造","BK4022":"陆运","BK0183":"MSCI概念","BK0188":"融资融券"},"translate_title":"天士力药业签署CAR-T药物合作协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600535":0.9,"CAR":1.5},"content_text":"Tasly Pharmaceutical (SHA:600535) signed a cooperation agreement for the research and development and marketing of a dual-target CAR-T, according to a Shanghai bourse filing on Friday.The contract was signed with Beijing Neurosurgical Institute and Beijing Renceng Neuro-Oncology Biotechnology Engineering Research Center.All parties will develop the drug, sharing research and development costs of up to 240 million yuan. Tasly exclusively owns the manufacturing and commercialization of the drugs.The drug, which is undergoing phase I clinical trials, was developed for the treatment of recurrent glioblastoma. It is targeting CD44 and/or CD133.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620004206","isCrawlerRequest":true}